Overview

Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the overall response rate (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally advanced or metastatic non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Peregrine Pharmaceuticals
Treatments:
Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Bavituximab
Carboplatin
Paclitaxel